This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Dec;19(3):337-8.

doi: 10.1385/JMN:19:3:337.

Tau as a drug target in Alzheimer's disease

Affiliations

PMID: 12540061
DOI: 10.1385/JMN:19:3:337

Editorial

Tau as a drug target in Alzheimer's disease

Illana Gozes. J Mol Neurosci. 2002 Dec.

. 2002 Dec;19(3):337-8.

doi: 10.1385/JMN:19:3:337.

Author

Affiliation

¹ Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. igozes@post.tau.ac.il

PMID: 12540061
DOI: 10.1385/JMN:19:3:337

No abstract available

PubMed Disclaimer

Similar articles

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L. Leclerc S, et al. J Biol Chem. 2001 Jan 5;276(1):251-60. doi: 10.1074/jbc.M002466200. J Biol Chem. 2001. PMID: 11013232
Alzheimer's disease. Pinning down phosphorylated tau.
Goedert M. Goedert M. Nature. 1999 Jun 24;399(6738):739-40. doi: 10.1038/21550. Nature. 1999. PMID: 10391237 No abstract available.
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.
Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. Lu PJ, et al. Nature. 1999 Jun 24;399(6738):784-8. doi: 10.1038/21650. Nature. 1999. PMID: 10391244
Cdk5 as a drug target for the treatment of Alzheimer's disease.
Lau LF, Seymour PA, Sanner MA, Schachter JB. Lau LF, et al. J Mol Neurosci. 2002 Dec;19(3):267-73. doi: 10.1385/JMN:19:3:267. J Mol Neurosci. 2002. PMID: 12540052 Review.
Pin1: a new outlook in Alzheimer's disease.
Lonati E, Masserini M, Bulbarelli A. Lonati E, et al. Curr Alzheimer Res. 2011 Sep;8(6):615-22. doi: 10.2174/156720511796717140. Curr Alzheimer Res. 2011. PMID: 21605045 Review.

See all similar articles

Cited by

Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.
Gozes I. Gozes I. EPMA J. 2010 Jun;1(2):305-16. doi: 10.1007/s13167-010-0029-y. Epub 2010 Jun 12. EPMA J. 2010. PMID: 23199066 Free PMC article.
Tau Diagnostics and Clinical Studies.
Gozes I, Höglinger G, Quinn JP, Hooper NM, Höglund K. Gozes I, et al. J Mol Neurosci. 2017 Oct;63(2):123-130. doi: 10.1007/s12031-017-0983-0. J Mol Neurosci. 2017. PMID: 29082468
Increased phosphorylation of tau and synaptic protein loss in the aged transgenic mice expressing familiar Alzheimer's disease-linked presenilin 1 mutation.
Yang X, Yang Y, Liu J, Li G, Yang E. Yang X, et al. Neurochem Res. 2012 Jan;37(1):15-22. doi: 10.1007/s11064-011-0575-2. Epub 2011 Aug 13. Neurochem Res. 2012. PMID: 21842270
The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience.
Gozes I. Gozes I. J Mol Neurosci. 2016 Nov;60(3):410-411. doi: 10.1007/s12031-016-0841-5. J Mol Neurosci. 2016. PMID: 27647306 No abstract available.
Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.
Gozes I. Gozes I. J Mol Neurosci. 2004;24(3):333-6. doi: 10.1385/JMN:24:3:333. J Mol Neurosci. 2004. PMID: 15655257 No abstract available.

See all "Cited by" articles

References

1. Nature. 1978 Nov 23;276(5686):411-3 - PubMed
1. J Physiol (Paris). 1990;84(1):134-7 - PubMed
1. J Mol Neurosci. 1999 Apr;12(2):131-45 - PubMed
1. Neurochem Int. 2001 Nov-Dec;39(5-6):341-8 - PubMed
1. Nature. 1981 Dec 3;294(5840):477-80 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal